Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative...

Area of Science:

• Genetics
• Molecular Biology
• Oncology

Background:

• Polycomb Repressive Complex 2 (PRC2) is a key epigenetic regulator of gene expression.
• Mutations in EZH2, a PRC2 component, are known in myeloid disorders.
• The roles of other PRC2 components (SUZ12, EED) and associated factors (JARID2) in these diseases are less understood.

Purpose of the Study:

• To investigate mutations in SUZ12, EED, and JARID2 in patients with myeloid disorders.
• To determine if these mutations affect PRC2 function.

Main Methods:

• Screening of SUZ12, EED, and JARID2 genes for mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasms and myelofibrosis.
• Analysis of mutations in relation to chromosomal abnormalities (17q UPD, 17q deletions).
• In vitro assays to assess the impact of identified mutations on PRC2 histone methyltransferase activity.

Main Results:

• SUZ12 mutations were found in patients with specific chromosomal abnormalities (17q UPD, 17q deletions) and in unselected cases (1.4% frequency).
• Missense mutations in the VEFS domain of SUZ12 were identified.
• Mutations in EED (1%) and JARID2 (2%) were also found in unselected cases.
• Tested SUZ12 and EED mutations reduced PRC2 methyltransferase activity in vitro.

Conclusions:

• SUZ12, EED, and JARID2 are potential mutational targets in myeloid disorders.
• Mutations in these genes can compromise PRC2 function, contributing to disease pathogenesis.
• These findings expand the understanding of genetic alterations in myeloid malignancies.